Renal Cell Carcinoma News

Toxicity-driven Sunitinib Dosing Improves Outcomes in RCC

Toxicity-driven Sunitinib Dosing Improves Outcomes in RCC

Toxicity-driven dosing of sunitinib improved response rates and survival compared with historical standard dosing among patients with metastatic renal cell carcinoma.

Plasma HGF Levels During Treatment Prognostic for Survival in RCC

Plasma HGF Levels During Treatment Prognostic for Survival in RCC

Patients with a decline in HGF levels had longer overall survival than those with high levels at baseline and at 4 weeks.

Two-to-One Sunitinib Schedule Fails To Reduce Toxicity

Two-to-One Sunitinib Schedule Fails To Reduce Toxicity

A modified dosing schedule of sunitinib did not improve adverse events rates among patients with metastatic renal cell carcinoma.

Characterization of Immune Cells in the RCC Tumor Microenvironment

Characterization of Immune Cells in the RCC Tumor Microenvironment

Overall, 3.5 million cells were analyzed and 17 major tumor-associated macrophage phenotypes were identified.

Varlilumab Active and Well-tolerated in Solid Tumors

Varlilumab Active and Well-tolerated in Solid Tumors

This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.

99mTc-MIBI SPECT/CT Differentiates Between Benign, Malignant Kidney Tumors

99mTc-MIBI SPECT/CT Differentiates Between Benign, Malignant Kidney Tumors

Study results suggest that 99mTc-MIBI SPECT/CT use can improve the differentiation between benign and malignant kidney tumors.

Cabozantinib for Pediatric Renal Cell Carcinoma: Two Case Studies

Cabozantinib for Pediatric Renal Cell Carcinoma: Two Case Studies

Two children with recurrent metastatic, TFE3 fusion-positive RCC that expressed MET experienced "prolonged disease control" following treatment with cabozantinib.

BET Inhibition Might Be Active Against Renal Cell Carcinoma

BET Inhibition Might Be Active Against Renal Cell Carcinoma

Study findings suggest that BET inhibitors might be a promising avenue of drug-development against RCC.

Clinician Communication, Perceived Burden Critical for Adherence to Oral Chemotherapy

Clinician Communication, Perceived Burden Critical for Adherence to Oral Chemotherapy

Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.

RCC: Computer-assisted Tumor Response Reduces Evaluation Errors

RCC: Computer-assisted Tumor Response Reduces Evaluation Errors

Computer-assisted evaluation of tumor response reduced errors and time of evaluation compared with standard-of-care.

Cryoablation May Offer Oncologic Control in cT1 Solitary Renal Masses

Cryoablation May Offer Oncologic Control in cT1 Solitary Renal Masses

Cryoablation was associated with good short-term oncologic control and an excellent safety profile in "healthier" patients.

Genetic Conditions and Renal Cell Carcinoma

Genetic Conditions and Renal Cell Carcinoma

The understanding of genetic conditions with predisposition to renal cell cancer is critical for developing better therapies.

Safety of Active Surveillance for Small Renal Masses

Safety of Active Surveillance for Small Renal Masses

Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.

Genomic Alterations in Metastatic Renal Cell Carcinoma

Genomic Alterations in Metastatic Renal Cell Carcinoma

Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.

Impact of Early Immunotherapy Discontinuation in mRCC

Impact of Early Immunotherapy Discontinuation in mRCC

Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.

ABX May Affect Efficacy of Checkpoint Inhibitors in RCC

ABX May Affect Efficacy of Checkpoint Inhibitors in RCC

Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.

Fumarate Hydratase Mutations and Renal Tumors: When Is Genetic Testing Appropriate?

Fumarate Hydratase Mutations and Renal Tumors: When Is Genetic Testing Appropriate?

Patients with kidney tumors with pathology indicating a fumarate hydratase (FH) mutation should be referred for genetic testing.

ASCO Releases Guideline for the Management of Small Renal Masses

ASCO Releases Guideline for the Management of Small Renal Masses

ASCO published new recommendations for the management of patients with clinically localized small renal masses (SRMs).

Dalantercept and Axitinib in Renal Cell Carcinoma

Dalantercept and Axitinib in Renal Cell Carcinoma

Combining dalantercept with axitinib treatment may improve clinical outcomes for previously treated patients with renal cell carcinoma (RCC).

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters